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Prostate cancer represents the second highest malignancy rate in men in all cancer diagnoses worldwide.
The development and progression of prostate cancer is not completely understood yet at molecular level,
but it has been reported that changes in the N-glycosylation of prostate-specific antigen (PSA) occur
during tumor genesis. In this paper we report on the development and implementation of a high-
throughput capillary electrophoresis based glycan analysis workflow for urinary PSA analysis. The
technology utilizes selective, high yield single domain antibody based PSA capture, followed by pre-
concentration and capillary electrophoresis coupled with laser-induced fluorescence detection, resultingspecific antigen; aPSA, anti
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sdAbin high resolution N-glycan profiles. Urinary PSA glycan profiles were compared to a commercially
available PSA standard revealing differences in their a2,3- and a2,6-sialylated isomers, proving the
excellent selectivity of the suggested workflow. This is important as sialylation classification plays an
important role in the differentiation between indolent, significant and aggressive forms of prostate
cancer.
© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer (PCa) has the second highest frequency rate in
men, with 21 % of all cancer diagnoses worldwide [1]. Currently, the
gold standard biomarker for PCa is the serum prostate specific
antigen (PSA) level. PSA, also known as human kallikrein 3 (KLK3 or
hK3), is an organ-specific glycoprotein, which plays an important
role in the liquefaction of semen [2]. It is produced by the prostate
epithelial cells and secreted primarily into the prostate but also
present in other body fluids, like blood and urine. Certain diseases,
like PCa or benign prostate hyperplasia and prostate related sur-
geries and/or biopsies can cause elevated PSA level in the blood-
stream [3]. Serum PSA assays greatly reduced the mortality rate of
PCa, but the number of false positive diagnoses steeply increased
[1]. To overcome the lack of specificity, the search for better PCa
biomarkers has been intensified is the last decades [4]. As in
numerous other cancer types, protein glycosylation seemed to be a
promising diagnostic target [5]. The link between PCa and changes
in PSA glycosylation has been reported in several studies [6e9]. The
most common cancer-associated N-glycosylation-related alter-
ations were found in sialylation (especially a2,3-sialylation) [10],
fucosylation (mainly core fucosylation, i.e., addition of fucose to the
innermost GlcNAc residue in the vicinity of the polypeptide back-
bone), O-glycan truncation (presence of shortened O-glycans),
extensive branching of N- and O-glycans (i.e., due to increased ac-
tivity of N-acetylglucosaminyltransferase) and the presence of
polysialic acid [11e15].
Awide repertoire of bioanalytical tools are available to detect N-
glycosylation alterations in human body fluid proteins. Numerous
lectin-based biosensors have been developed to recognize certain
sugar structures (e.g., a2,6- and a2,3-sialylation) [16] and instru-
mental analysis by mass spectroscopy, liquid chromatography,
capillary electrophoresis, or their various combinations have also
been applied for PSA N-glycosylation analysis [17]. However, in
spite of these extensive studies, only a few reported methods were
capable to achieve full N-glycanmapping with the separation of the
critical structural elements. In addition, these techniques usually
required special reagents or complex instrumentation [9,18]. The
biological source of PSA is also critical. Semen, blood, and urine are
the most commonly used body fluids for this purpose. Standard,
commercially available PSA is obtained from human semen, as it
contains PSA in the highest concentration (approximately 1.3 mg/
ml) [19], but its usage in clinical analysis is very limited. Blood is
much easier to collect (even though it is a somewhat invasive
procedure), therefore, it is frequently applied as a viable sample
source. Unfortunately, the PSA concentration in blood is usually
very low (<10 ng/ml), which can make extensive qualitative anal-
ysis a challenge. Urine contains a higher amount of PSA (~100 ng/ml
[20]), but its concentration can change over a wide range. It is
important to note that compared to blood and semen, the urine
matrix possesses significantly lower amounts of glycoproteins,
which could otherwise interfere with glycosylation analysis.
To obtain high sensitivity results of low concentration bio-
markers, sample preconcentration is often required. Specific2
capture of PSA frombiological matrices is also beneficial to filter out
any non-PSA related sugar or protein impurities, which could alter
the analysis results. Monoclonal antibodies are commonly used
capturing agents [21], but their accessibility can limit their appli-
cation. In addition, they are glycoproteins, therefore, their removal
from the sample prior to analysis is often necessary to avoid any
possible interferences. Single domain antibodies (sdAbs) often
dubbed as nanobodies, on the other hand, can alleviate this
drawback [22]. They are much smaller in size, can be readily pro-
duced in bacteria, thus, do not contain sugar moieties. Also, sdAbs
can be expressed with different linker tags (e.g., 6-histidine tag) to
facilitate their oriented (higher capture efficiency) immobilization
to various stationary surfaces [23].
In this paper, a novel workflow is presented for CE-based
comprehensive N-glycan analysis of urinary PSA. The process
starts with sample concentration steps followed by selective, high
yield sdAb-based PSA capture. Thereafter, the N-glycans were
enzymatically released from the enriched PSA, fluorescently
labeled by aminopyrene trisulfonic acid and analyzed by CE-LIF. The
corresponding N-glycan structures were first identified by their
glucose unit (GU) values and verified by exoglycosidase based
automated carbohydrate sequencing.2. Materials and methods
2.1. Chemicals and reagents
Water (HPLC grade), acetic acid (glacial), acetonitrile (MeCN),
sodium cyanoborohydride (1 M in THF), sodium chloride, imid-
azole, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
and DTT (dithiothreitol) were obtained from Sigma Aldrich (St.
Louis, MO, USA). SDS (sodium dodecyl sulfate) and Nonidet P-40
were from VWR (West Chester, PA, USA). The Fast Glycan Labeling
and Analysis Kit was from SCIEX (Brea, CA, USA) including the
tagging dye of 8-aminopyrene-1,3,6-trisulfonic acid (APTS), mag-
netic beads for excess dye removal, HR-NCHO separation gel-buffer
system as well as the bracketing standards of maltose (DP2) and
maltopentadecaose (DP15). The exoglycosidase enzymes of Siali-
dase A (Arthrobacter ureafaciens), b-Galactosidase (Jack bean) and
b-N-Acetyl Hexosaminidase (Jack bean) were from Agilent (Hay-
ward, CA, USA). The endoglycosidase PNGase F was from Asparia
Glycomics, (San Sebastian, Spain). 20 ml volume 10 kDa cut-off
spinfilters were from Pall (New York, NY, USA), 500 ml ml volume
10 kDa cut-off spinfilters were from VWR. PhyTip Ni-IMAC micro-
columns (40 ml) were provided by PhyNexus (San Jose, CA). Buffer
‘A’: 100 mMHEPES, 500 mMNaCl, 50 mM imidazole (pH¼ 8.0) and
Buffer ‘B’: 100 mM HEPES, 500 mM NaCl, 500 mM imidazole
(pH ¼ 8.0). Denaturation solution: mixture of Nonidet P-
40:DTT:SDS ¼ 6:1:1. Digestion solution: 75 munit/ml of PNGase F in
16.7 mM ammonium acetate. Labeling solution: 5.7 mM of APTS in
the mixture of H2O:AcOH:THF:NaBH3CN (1 M in THF) ¼ 5:5:8:2.
Magnetic bead based purification solution: the solvent was
removed from200 ml of magnetic bead suspension from Fast Glycan
Labeling and Analysis Kit on amagnetic stand. Next, the beads were
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on amagnetic stand, and the beads were resuspended again in 20 ml
of water.2.2. Expression and purification for PSA specific sdAb
Two sdAb coding sequences, N7 and C9 [24] were codon opti-
mized for E. coli, the genes with flanking 50-NdeI and 30-XhoI
cleavage sites were synthetized by Genscript (Piscataway, New
Jersey, United States) and cloned into pET23b expression vector
(Novagen, Merck, Darmstadt, Germany). Shuffle T7 Express E. coli
(New England Biolabs, Ipswich, Massachusetts, US) cells were
transformed with the plasmids, according to the supplier's protocol
(Fig. 1). 5 mL LB/Amp preculture was prepared as reported earlier
[25], and 2mL of the resuspended cells was used to inoculate 1 L LB/
Amp. The cell culturewas grown at 37 C and then at 30 C,140 rpm
in baffled flask until OD600 reached 0.6e1.0 range. Protein
expression was induced by the addition of 0.5 mM isopropyl b-D-1-
thiogalactopyranoside (IPTG) and incubated overnight at 22 C. The
cells were harvested by centrifugation at 6000g for 30 min,
washed with buffer ‘A’. Cells were resuspended on ice in 20 ml
buffer ‘A’ containing EDTA-free Mini Complete protease inhibitor
(Roche, Basel, Switzerland) and disrupted by sonication (10  30 s,
50 % amplitude). After centrifugation and filtration the supernatant
was loaded onto a Ni(II)-saturated, pre-equilibrated 5 ml HiTrap
Chelating (GE Healthcare, Chicago, Illinois, US) column and purified
using isocratic elution. The pure proteinwas eluted at 50 % ‘B’ buffer
and dialyzed. Purity of sdAb was confirmed on 15 % SDS PAGE gels
and protein concentration calculated using the following parame-
ters given by ProtParam [26]: N7-aPSA-6His, 14.5 kDa,
27,180 cm1M1 and C9-aPSA-6His, 14.3 kDa, 21,555 cm1M1,
respectively.2.3. Biological specimens
Urine samples were collected with the appropriate Ethical Per-
missions (approval number: 23580e1/2015/EKU (0180/15)) and
Informed Patient Consents in the Semmelweis Hospital (Miskolc,Fig. 1. Schematics of the single domain anti-PSA production. Genes of strong PSA binder N
proteins were produced in SHuffle T7 Express E. coli cells. SHuffle ensured the proper for
functional antibody for selective capture of PSA from body fluids.
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Hungary). Samples were taken from male and female (blind con-
trol) healthy volunteers (seven Caucasian subjects, age average:
28.3, age median 27) and kept at 4 C until processing.2.4. PSA quantitation in urine
PSA quantitation was carried out by standard ELISA assays in an
UniCel DxI 800 Access Immunoassay System, kindly provided by
the central laboratory of Csolnoky Ferenc Hospital (Veszprem,
Hungary). Urine samples were analyzed directly, without any
sample preparation.2.5. PSA capture from urine
300ml of male urinewas cooled to room temperature and it was
concentrated to 500 ml by 20 ml volume 10 kDa cut-off spinfilters
(13,500g for 30 min at 6 C for each consecutive 20 ml concen-
tration). The concentrated urine was diluted and centrifuged
(13,500g for 10 min at 6 C) twice with 3-3 ml of buffer ‘A’ then it
was transferred to an Eppendorf vial. The filter was washed two
times with 250 ml buffer ‘A’ each and both were added to the
transferred urine. The final, 1 ml mixture was vortexed and divided
into to 500-500 ml, one for PSA capture and one for control. Two Ni-
IMAC microcolumns were washed by 200 ml buffer ‘A’ for 5 min, by
connecting the tips to an automated pipette and the buffer was
continuously aspirated and dispensed through the tips with the
flow rate of 2 ml/min. In the next step, the tips were washed by
50 mg/ml C9 sdAb in 100 ml buffer ‘A’ for 10 min. For the control,
100 ml buffer ‘A’ without sdAb was used. Both tips were washed
again by 200 ml buffer ‘A’ for 5 min. Then, the tips were rinsed by
500-500 ml concentrated urine samples for 10 min. After that, the
tips werewashed again 3 times with 200 ml of buffer ‘A’, 5 min each,
then washed by 100 ml buffer ‘B’ for 5 min. The elutes were trans-
ferred onto 500 ml volume 10 kDa cut-off spinfilters and the solvent
was centrifuged (13,500g for 10 min at 6 C). The filter was
washed twice by 400 ml of water, both times the water was
centrifuged (13,500g for 10 min at 6 C). The samples were taken
up into 80 ml water (washing the filter twice with 40-40 ml of7 and C9 sdAb variants were incorporated into the pET23b expression vector and the
mation of disulfide bonds, thus appropriate folding of sdAb, resulting in soluble and
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SpeedVac under reduced pressure at 70 C for 15 min. The dried
sample was resolved again in 10 ml of water.2.6. Sample preparation
The sample preparation process was identical for all captured
PSA, control and PSA standard (150 mg/ml) samples. 2 ml of dena-
turation solution was added to 10 ml sample, and heated up from
30 C to 80 C in 8 min 20 s and incubated at 80 C for an additional
100 s. Then 20 ml of digestion solution was added and the sample
was heated up from 40 C to 60 C in 20 min. After that, the APTS
labeling solution was added and the reaction mixture was incu-
bated at 37 C overnight in an open cap vial to let the solvent
evaporate [27]. The dried sample was taken up in 20 ml of magnetic
bead suspension followed by the addition of 185 ml of MeCN and
supernatant was removed from the magnetic beads on a magnetic
stand. The beads were suspended in 20 ml of water, 185 ml of MeCN
was added and the solvent was removed from the magnetic beads
on a magnetic stand again. This step was repeated two additional
times (total of 4 washes with the first one adding the beads) as
reported in Ref. [28]. Finally, the beads were resuspended in 60 ml of
water and, on a magnetic stand, 50 ml of the supernatant was
transferred into a new vial for CE-LIF analysis.2.7. Capillary gel electrophoresis
A PA800 Plus Pharmaceutical Analysis System (SCIEX) with laser
induced fluorescence detection (lex ¼ 488 nm/lem ¼ 520 nm) was
used for all capillary gel electrophoresis separations employing the
HR-NCHO separation gel buffer in 40 cm and 20 cm effective length
(50 cm and 30 cm total length, 50 mm ID) bare fused silica capillary
columns, as specified under the corresponding figure captions. The
applied electric field strength was 30 kV in reversed polarity mode
(cathode at the injection side, anode at the detection side). The
separation temperaturewas set at 30 C. A three-step electrokinetic
sample injection was applied: 1) 3.0 psi for 5.0 s water pre-
injection, 2) 1.0 kV for 1.0 s sample injection and 3) 1.0 kV for
1.0 s bracketing standard (DP2 and DP15). The 32Karat (version
10.1) software package (SCIEX) was used for data acquisition and
interpretation.2.8. Glycan structure identification
Structural elucidation of the separated, asparagine linked PSA
glycans was first done by direct comparison of their GU values in
relevant database entries (GUcal.hu), and verified by exoglycosi-
dase digestion based carbohydrate sequencing [18,29]. Shortly, the
released N-glycans were consecutively digested by monomer and
anomericity specific exoglycosidase enzymes such as Sialidase A, b-
Galactosidase and b-N-Acetyl Hexosaminidase. The untreated and
all digested pools were then separated by CE-LIF and the structural
information was derived from the GU value shifts of the individual
peaks as the result of the exoglycosidase treatments [30].Fig. 2. Capillary electrophoresis separation of the APTS-labeled PSA standard N-gly-
come. Separation conditions: 50 cm total (40 cm effective) length, 50 mm i.d. bare fused
silica capillary with HR-NCHO gel buffer. Voltage: 30 kV (0.5 min ramp); Temperature:
25 C; Injection: 5 psi/5 s water pre-injection followed by 5 kV/2 s sample. Structures
corresponding to the numbered peaks are listed in Table 1.3. Results and discussion
A novel, integrated workflowwas established for urinary PSA N-
glycosylation analysis utilizing highly selective sdAb-based capture
from urine, high throughput preconcentration, enzymatic release
of N-glycans from the captured PSA, fluorescent carbohydrate la-
beling, high resolution capillary electrophoresis separation and
comprehensive glycan structure elucidation.4
3.1. Analysis of the standard PSA N-glycom
First, the global N-glycosylation profile of a commercial PSA
standard was analyzed in order to establish a reference point for
the workflow development process. As Fig. 2 depicts, high resolu-
tion glycan profile was obtained with the 30 most significant peaks
annotated. The abbreviated names, structures, migration times and
GU values of all identified glycans are listed in Table 1. 15 structures
from the PSA standard were only a2,6-sialylated, 9 only a2,3-
sialylated and 6 contained both a2,3- and a2,6-sialylation. Core
fucosylation was found on 14 glycans, as well as 6 tri-antennary, 2
bisecting and 2 hybrid type structures were identified. The exo-
glycosidase based glycan sequencing process is shown in Fig. 3,
utilizing Sialidase A, b-Galactosidase and b-N-Acetyl Hexosamini-
dase, depicted by the corresponding traces. Sequence information
was derived from the GU value shifts of the individual peaks as the
result of the consecutive exoglycosidase treatments as described in
Ref. [30]. Structures marked with an asterisk are assumable contain
N-acetylgalactosamine (NAG) instead of galactose (G) on one of the
branches. These structures were identified only by their GU values,
because no specific enzyme was available to selectively release
NAG. During identification, the peaks denoted by asterisks were
compared to structures with galactose on both of their branches.
Peak 37 has 0.5 higher GU value than peak 35 (A2G2) and peak 40
similarly 0.5 GU higher compared to peak 38 (F(6)A2G2). After b-
Galactosidase digestion peak 35 moves into peak 44 (A2G2/A2)
and 38 into 45 (F(6)A2G2/F(6)A2), while peak 37 into 48
(A2G1NAG1/A2NAG1) and 40 into 49 (F(6)A2G1NAG1/F(6)
A2NAG1). Due to the digestion process, the GU value decreased 2.3
times more in case of G2 structures compared to their G1NAG1
counterparts. The exact same ratio can be observed in the GU value
change after b-N-Acetyl Hexosaminidase digestion between the
two variants. The difference implies that while both branches are
digested at structures containing G2, only one branch is digested
from the G1NAG1 counterparts and probably the NAG containing
branch stays intact. Notably, comparing the sialylated G2 structures
to their G1NAG1 counterparts (peak 547, 9410, 11412, 13414,
19420, 22423, 25427, 28430) the GU difference is relatively
Table 1
Identified glycan structures from PSA standard and glycan sequencing. Structural interpretation follows the suggestions of [32].
Glycan origin Peak No. Migration time (min) GU Glycan name Glycan structure
Native PSA 1 9.82 4.24 A3G(4)3S(6,6,3,6)4
2 9.91 4.35 A3G(4)3S(3,6,3,6)4
3 9.96 4.41 A3G3(6,6,6)S3
4 10.03 4.51 A3G3(6,6,3)S3
5 10.21 4.73 A2G2(6,6)S2
6 10.25 4.79 A1 [6]G(4)1(6)S1
7 10.30 4.85 A2G1NAG [6]1(6,6)S2*
8 10.34 4.90 A2G2(3,6)S2
9 10.41 4.99 F(6)A2G2(6,6)S2
10 10.50 5.11 F(6)A2G1NAG [6]1(6,6)S2*
11 10.54 5.18 F(6)A2G2(3,6)S2
12 10.63 5.30 F(6)A2G1NAG [6]1(3,6)S2*
13 10.71 5.41 F(6)A2G2(3,3)S2
14 10.82 5.56 F(6)A2G1NAG [6]1(3,3)S2*
15 10.92 5.71 A3G3(6,6)S2
16 10.99 5.80 F(6)A2 [6]G(4)1(6)S1
17 11.04 5.87 F(6)A2 [3]G(4)1(6)S1
18 11.15 6.03 M5A1G1(6)S1
19 11.23 6.16 A2G2(6)S1
(continued on next page)
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Table 1 (continued )
Glycan origin Peak No. Migration time (min) GU Glycan name Glycan structure
20 11.27 6.21 A2G1NAG1(6)S1*
21 11.33 6.31 A3G3(3,3)S2
22 11.37 6.36 M5A1G1(3)S1
23 11.48 6.53 A2G2(3)S1
24 11.53 6.60 A2G1NAG1(3)S1*
25 11.65 6.78 F(6)A2G2(6)S1
26 11.69 6.85 F(6)A2BG2S(6)1
27 11.76 6.96 F(6)A2G1NAG1(6)S1*
28 11.84 7.08 F(6)A2G2(3)S1
29 11.89 7.16 F(6)A2BG2S(3)1
30 12.04 7.39 F(6)A2G1NAG1(3)S1*
Sequencing 31 11.67 6.82 A1G1
32 12.29 7.79 A2 [6]G1
33 12.56 8.22 F(6)A1 [3]G1
34 13.12 9.11 F(6)A2 [3]G1 þ M5A1G1
35 13.17 9.20 A2G2
36 13.39 9.54 F(6)A2BG1
37 13.49 9.70 A2G1NAG1*
38 13.77 10.14 F(6)A2G2
39 14.01 10.52 F(6)A2BG2
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Table 1 (continued )
Glycan origin Peak No. Migration time (min) GU Glycan name Glycan structure
40 14.06 10.60 F(6)A2G1NAG1*
41 14.28 10.96 A3 [6]G3
42 14.52 11.35 A3 [3]G3
43 11.02 5.86 A1
44 11.60 6.72 A2
45 12.21 7.67 F(6)A2
46 12.27 7.77 M5A1
47 12.40 7.97 A3
48 12.80 8.61 A2NAG1*
49 13.38 9.53 F(6)A2NAG1*
50 10.33 4.89 M3
51 10.84 5.60 F(6)M3
52 11.66 6.81 M5
53 12.26 7.75 A1NAG1*
54 12.81 8.63 F(6)A1NAG1*
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structures on the PSA standard sample were sialylated, empha-
sizing the advantage of CE-LIF as a gentle separation technique
being able to preserve such sensitive glycan isomers. Orthogonal
techniques, like MS often leads to de-sialylation due to in-source
degradation [31]. A common concern about the MS analysis is
that a2,6-sialylated and a2,3-sialylated glycopeptides have similar
or even identical CID fragmentation patterns, which makes linkage
specific identification difficult. Furthermore, in many cases, accu-
rate structural elucidation by MS/MS is not possible due to the7
relatively poor signal intensity. However, the high resolution of the
suggested CE-LIF method presented here was capable to readily
differentiate the a2,3- and a2,6-sialylated isomers on mono- or
multi-sialylated structures, which could be key for cancer diag-
nosis. Other PCa related alterations, like the degree of core fuco-
sylation or branching could also be traceable, especially after
exoglycosidase mediated sequencing. Both, the number of identi-
fied glycans as well as the excellent resolution with reliably track-
able ratios of the given structures proved the great potential of this
workflow as a possible high selectivity PCa diagnostic tool.
Fig. 3. Exoglycosidase based carbohydrate sequencing of the N-glycome of the PSA
standard. (A) untreated PSA standard; (B) after Sialidase A, (C) after Sialidase A þ b-
Galactosidase and (D) after Sialidase A þ b-Galactosidase þ b-N-Acetyl Hexosamini-
dase digestion. Separation conditions were the same as in Fig. 2. Structures corre-
sponding to the numbered peaks are listed in Table 1.
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Several sdAb single domain antibody sequences were selected
earlier by phage display using a variant library prepared from the
variable domain of the heavy-chain antibody of dromedary
immunized with PSA [24]. The two strongest PSA binder variants,
namely N7 (Kd ¼ 0.16 nM) and C9 (Kd ¼ 4.7 nM) were expressed
with C-terminal histidine tags to facilitate easy immobilization for
affinity based PSA capture from urine.
The cysteine content of the C9 and N7 sdAb variants makes
proper folding less effective in standard E. coli strains. Additionally,
two cysteines of N7 sdAb are located in the variable regions and
supposedly form a stabilizing disulfide bond on the surface of the
molecule. For this reason, we used Shuffle T7 Express cells for
protein expression, which is an engineered E. coli B strain capable to
promote disulfide bond formation in the cytoplasm [33,34]. As a
result of our optimized production protocol, the typical yield for the
sdAb variants was 8e12 mg/L culture.3.3. PSA capture procedure
Scouting experiments suggested that the limit of detection
(LoD) was approximately 500 ng of PSA standard in 10 ml sample for
the CE-LIF analysis of released N-glycans. Taking the LoD value into
consideration for selecting the optimal biological sample source,
blood was excluded due to its very low PSA concentration. Standard
PSA-ELISA tests of urine samples from healthy volunteers resulted
in an average concentration of 60 ng/ml (slightly lower comparing
to literature data [20]) with a maximum of 120 ng/ml and a mini-
mum of 30 ng/ml. Results varied on a large scale between the
samples from different patients as well as from the same patient8
but different sampling dates. The PSA-ELISAmethodwas developed
for testing blood PSA level, thus a female urine sample was also
processed as negative control, resulting in 0 ng/ml PSA. Female
urine was also spiked with PSA standard for positive control,
resulting in the added concentration. Control results suggested that
the urine matrix did not affect the accuracy of PSA-ELISA tests.
Considering the lowest concentration, a minimum requirement
was 150 ml of urine to reliably obtain sufficient quantity of PSA for
capture and analysis.
To immobilize the sdAbs, Ni-IMAC microcolumns were chosen
(Fig. 4/1a) as they showed strong affinity for the histidine tags of
the nanobodies. In order to effectively introduce all of the biological
matrix to the column, the volume of urine had to be reduced to 1ml
(i.e., to fit in a 1000 mL affinity columns). Simple heating based
evaporation of thewater content of the samples was problematic as
the higher temperature could lead to possible loss of sensitive sialic
residues and precipitation. Therefore, 10 kDa cut-off value filters
were utilized (Fig. 4/1b), which retained PSA effectively, while
letting through the solvent and small contaminants (e.g., sugars).
Changing the urinary matrix to buffer was beneficial in multiple
levels. It contributed to avoid any possible undesirable effect on the
sdAb capture due to the variable urinary pH as well as introduced
imidazole as an agent to prevent non-specific bindings of some of
the remaining (>10 kDa) urine components.
The capture capabilities of both sdAB variants of C9 and N7were
tested. Despite of the different equilibrium binding constants, they
resulted in equally high yields in terms of signal intensity in CE-LIF
analysis, when their binding capacities were tested in preliminary
experiments by PSA standard capture from buffer solution (data not
shown). Our final choice was the C9 variant, as it provided slightly
higher production yields. Various methods were also tested during
the elution step (Fig. 4/3) (denaturation, addition of EDTA, etc.) and
the addition 500 mM imidazole solution proved to be the best to
remove the nanobody-antigen complex from the column. Based on
the common knowledge that E. coli does not have the machinery to
glycosylate proteins, we considered the resulting sdAbs not glyco-
sylated, i.e., its removal from the sample was not necessary. How-
ever, changing the buffer for water was required after the elution
(Fig. 4/4) as the high salt concentration interfered with the removal
of excess labeling dye later in the sample preparation workflow.
The initial test of the capture method was done with a the PSA
standard, spiked into buffer ‘A’ solution. The glycan profile of the
captured PSA corresponded to the PSA standard profile (Fig. 5. D).
To evaluate the matrix effect of urine, PSA standard was also spiked
into female urine and captured, resulting similar yields in analytical
signal compared to the spiked buffer, as well as, similar glycan
profile (Fig. 5. C) as of the PSA standard, suggesting that the sdAb
capturing ability was not affected negatively by the matrix. The
results of concentrated and captured male urine were also corre-
sponding with both spiked test mixtures (Fig. 5. B). To verify that all
the resulted glycans originated from urinary or spiked PSA, intact
female urine was used as a control (Fig. 5. A), in which case no PSA
related peaks were detected. Nineteen N-glycan structures were
identified from the captured male urinary PSA and their peak area
distribution was found to be almost identical to the corresponding
PSA standard pool. Please note, 20 cm effective length capillary was
utilized for the separation of the captured urinary PSA glycans as
we aimed to develop a fast, high-throughput method, which can be
readily adapted into clinical laboratory settings, even in a multi-
capillary format to increase throughput. No desialylated glycans
were found, proving that both the analytical part and the selective
capture procedure were sufficiently mild enough to preserve sen-
sitive sugar structures, e.g., sialic acids. As with the PSA standard,
the a2,3- and a2,6-sialylated isomers were separated on both
mono- and multi-sialylated structures, as well as, the core
Fig. 4. Urinary PSA analysis workflow. 1a) Immobilization of sdAb to Ni-IMAC column; 1b) Concentration of urine via spinfilters; 2) PSA capture from urinary matrix; 3) Elution of
antibody-PSA complex; 4) Desalting and concentration; 5) Denaturation of PSA; 6) N-glycan release by PNGase F digestion; 7) Fluorescent glycan labeling; 8) CE-LIF analysis.
Fig. 5. Capillary electrophoresis separation of the sdAb captured PSA N-glycome pools.
A) intact female urine control, B) male urinary PSA N-glycome, C) PSA standard spiked
into female urine, D) PSA standard spiked into buffer ‘A’. Separation conditions: 30 cm
total (20 cm effective) length, 50 mm i.d. bare fused silica capillary with HR-NCHO gel
buffer. Voltage: 30 kV (0.5 min ramp); Temperature: 25 C; Injection: 5 psi/5 s water
pre-injection followed by 2 kV/2 s sample. Structures corresponding to peaks are listed
in Table 1.
B. Reider, E. Gacsi, H. Jankovics et al. Analytica Chimica Acta xxx (xxxx) xxxfucosylated or bisecting structures.4. Conclusions
In this paper a newworkflowwas introduced to isolate PSA from
urine samples by sdAbs immobilized IMAC-Ni microcolumns. The
sdAb was produced in-house and were engineered with a special
linker tag to help their anchoring to the stationary phase. The usage
of sdAbs over mAbs may facilitate extension of the application in
future clinical tests as their production even at larger quantities is9
possible with lower costs. The selective capturing procedure
contributed both to remove other glycoprotein contaminants from
the biological matrix and pre-concentrating the PSA content,
resulting in higher detection signal. The CE-LIF analysis of the
released glycans from urinary PSA resulted in 19 structures out of
the 30 obtained from a PSA standard. Each identified glycan
structure originated from the native PSA was sialylated, suggesting
that the mild conditions of both the capture and labeling/analysis
procedure preserved the labile sugar residues, especially the sialic
acids and core fucosylation. Due to the high resolving power of the
CE-LIF system, both the fucosylated and non-fucosylated structures
as well as the a2,3- and a2,6-sialylated isomers were separated.
Since the most common cancer related alterations are reportedly
associated with these structural changes, it is key for any diagnostic
application to reliably detect the alterations of these residues.
Furthermore, as individual structures were identified with high
resolution, more complex variations could be discovered, which
occurs in certain glycans only. Our results showed that the devel-
oped workflow was suitable for comprehensive N-glycan analysis
of urinary PSA and could be a basis for future endeavors aiming to
detect the alterations in PSA glycosylation caused by certain dis-
eases like prostate cancer or benign prostatic hyperplasia.CRediT authorship contribution statement
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